The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Abstract
Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) markedly reduces stroke and mortality in AF patients.38,39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“and hence there is strong evidence that patients with a CHA 2 DS 2 -VASc risk score of 2 or more in men, and 3 or more in women benefit from OAC.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke, 38,39,42,194,201,329,351,352”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Mortality was 10% lower in patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85-0.95;P = 0.0003) and intracranial haemorrhage was halved (RR 0.48; 95% CI 0.39-0.59;P < 0.0001), while gastrointestinal bleeding events were more frequent (RR 1.25; 95% CI 1.01-1.55;P = 0.04).39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“NOACs in these dosages significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73-0.91;P < 0.0001), mainly driven by a reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38-0.64;P < 0.0001).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“A meta-analysis 39 based on the highdose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a NOAC and 29,272 receiving warfarin.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Good data are available to support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged Study), 362 the NOAC trials, 39 and from analyses in elderly Americans (Medicare).396”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Cited by
Sorted by citations
Items 801–900 of 1,004
Hospitalized frail elderly patients – atrial fibrillation, anticoagulation and 12 months’ outcomes
Ekerstad, N., Karlsson, T., Söderqvist, S., & Karlson, B. W. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159373 · Cited by 38
How can we reverse bleeding in patients on direct oral anticoagulants?
Crowther, M. A., & Cuker, A. C. (2018) · Kardiologia Polska · doi:10.5603/kp.a2018.0197 · Cited by 39
The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
Hoffman, M., Goldstein, J. N., & Levy, J. H. (2018) · International Journal of Emergency Medicine · doi:10.1186/s12245-018-0215-6 · Cited by 39
Renda, G., Patti, G., Lang, I. M., Siller-Matula, J. M., Hylek, E. M., Ambrosio, G., Haas, S. K., & Caterina, R. D. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.004 · Cited by 39
Diener, H., Hankey, G. J., Easton, J. D., Lip, G. Y. H., Hart, R. G., & Caso, V. (2020) · European Heart Journal Supplements · doi:10.1093/eurheartj/suaa104 · Cited by 38
A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant
Wadsworth, D. C., Sullivan, E., Jacky, T., Sprague, T., Feinman, H., & Kim, J. (2021) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13343 · Cited by 40
Exploring stroke risk and prevention in China: insights from an outlier
Lin, X., Wang, H., Rong, X., Huang, R., & Peng, Y. (2021) · Aging · doi:10.18632/aging.203096 · Cited by 36
Benz, A. P., Xu, L., Eikelboom, J. W., Middeldorp, S., Milling, T. J., Crowther, M. A., Yue, P., Conley, P. B., Lu, G., Connolly, S. J., et al. (2022) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1740180 · Cited by 38
Fischer, U., Trelle, S., Branca, M., Salanti, G., Paciaroni, M., Ferrari, C., Abend, S., Beyeler, S., Strbian, D., Thomalla, G., et al. (2022) · European Stroke Journal · doi:10.1177/23969873221106043 · Cited by 32
Huang, L., Tan, Y., & Pan, Y. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14084 · Cited by 38
Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation
Cavallari, I. (2018) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.8256 · Cited by 38
Carnicelli, A., Hong, H., Giugliano, R. P., Connolly, S. J., Eikelboom, J. W., Patel, M. R., Wallentin, L. C., Morrow, D. A., WOJDYLA, D. M., Hua, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.12.002 · Cited by 37
Jannati, S., Patnaik, R., & Banerjee, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168727 · Cited by 43
Anticoagulation Management: Current Landscape and Future Trends
Kholmukhamedov, A., Subbotin, D., Gorin, A. A., & Ilyassov, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051647 · Cited by 45
2025 Clinical practice guidelines for Atrial fibrillation and flutter
Golukhova, E. Z., Sp, G., Михайлов, Е. Н., Revishvili, A. S. H., Arakelyan, M. G., Vasilyeva, E. Y., Davtyan, K. V., Drapkina, O. M., Drozdova, L. Y., Станиславовна, К. Е., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6668 · Cited by 44
Gurol, M. E. (2017) · Stroke · doi:10.1161/strokeaha.117.017081 · Cited by 36
Mechanical thrombectomy in orally anticoagulated patients with acute ischemic stroke
Zapata-Wainberg, G., Ximénez‐Carrillo, Á., Trillo, S., Fuentes, B., Cruz-Culebras, A., Aguirre, C., de Leciñana, M. A., Vera, R., Bárcena, E., Prieto, A., et al. (2017) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2017-013504 · Cited by 37
What Surgeons Should Know About Non–Vitamin K Oral Anticoagulants
Verma, A., Ha, A. C. T., Rutka, J. T., & Verma, S. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.0374 · Cited by 38
Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation
Heine, G. H., Brandenburg, V. M., & Schirmer, S. H. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0287 · Cited by 37
Reinecke, H., Juergensmeyer, S., Engelbertz, C. M., Gerß, J., Kirchhof, P. F., BREITHARDT, G. E., Bauersachs, R. M., & Wanner, C. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022690 · Cited by 39
Pham, P. N., & Brown, J. D. (2019) · BMC Cardiovascular Disorders · doi:10.1186/s12872-019-1033-3 · Cited by 37
Lee, S., Rhee, T., Kang, D., Choi, E., Oh, S., & Lip, G. Y. H. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.072 · Cited by 37
Verheugt, F. W. A., ten Berg, J. M., Storey, R. F., Cuisset, T., & Granger, C. B. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.080 · Cited by 40
Dalgaard, F., Pieper, K. S., Verheugt, F. W. A., Camm, A. J., Fox, K. A. A., Kakkar, A. K., Pallisgaard, J. L., Rasmussen, P. V., van Weert, H. C. P. M., Lindhardt, T. B., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-033283 · Cited by 38
Olsen, A. S., McGettigan, P., Gerds, T. A., Fosbøl, E. L., Olesen, J. B., Sindet‐Pedersen, C., Stærk, L., Hansen, M. L., Pallisgaard, J. L., Køber, L., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz069 · Cited by 41
Godino, C., Melillo, F., Bellini, B., Mazzucca, M., Pivato, C. A., Rubino, F., Figini, F., Mazzone, P., Bella, P. E. D., Margonato, A., et al. (2020) · EuroIntervention · doi:10.4244/eij-d-19-00507 · Cited by 37
Korff, M., Imberg, L., Will, J. M., Bückreiß, N., Kalinina, S. A., Wenzel, B., Kastner, G. A., Daniliuc, C. G., Barth, M., Ovsepyan, R. A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01635 · Cited by 38
Bayer, V., Kotalczyk, A., Kea, B., Teutsch, C., Larsen, P., Button, D. A., Huisman, M. V., Lip, G. Y. H., & Olshansky, B. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023907 · Cited by 37
Mołek, P., Ząbczyk, M., Malinowski, K. P., Natorska, J., & Undas, A. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.02.025 · Cited by 37
Grymonprez, M., de Backer, T. L., Bertels, X., Steurbaut, S., & Lahousse, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125576 · Cited by 37
Mamas, M. A., Batson, S., Pollock, K. G., Grundy, S., Matthew, A., Chapman, C., Manuel, J. A., Farooqui, U., & Mitchell, S. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.11.021 · Cited by 36
Salim, H. A., Musmar, B., Adeeb, N., Yedavalli, V. S., Lakhani, D. A., Grewal, S. S., Naamani, K. E., Henninger, N., Sundararajan, S. H., Kühn, A. L., et al. (2024) · European Stroke Journal · doi:10.1177/23969873241249295 · Cited by 36
Gudmundsdottir, K. K., Svennberg, E., Friberg, L., Hygrell, T., Frykman, V., Al‐Khalili, F., Hijazi, Z., Rosenqvist, M., & Engdahl, J. (2024) · Circulation · doi:10.1161/circulationaha.124.071176 · Cited by 36
Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation
Warach, S. J., Davis, L. A., Lawrence, P., Gajewski, B. J., Wick, J., Shi, F., Shang, T., Olson, D. M., Prasad, S., Birnbaum, L., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0285 · Cited by 36
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics
Duconge-Soler, J., Ramos, A. S., Claudio‐Campos, K., Rivera-Miranda, G. C., Bermúdez-Bosch, L., Renta, J. Y., Cadilla, C. L., Cruz, I., Feliu, J. F., Vergara, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145480 · Cited by 36
Steg, P. G., Halperin, J. L., Goldenberg, N. A., Schulman, S., Spyropoulos, A. C., Kessler, C. M., Turpie, A. G. G., Cutler, N. R., Hiatt, W. R., Kittelson, J. M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-12-1000 · Cited by 36
Medical management of intracerebral haemorrhage
Schreuder, F. H. B. M., Sato, S., Klijn, C. J. M., & Anderson, C. S. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314386 · Cited by 37
Urbaniak, A. M., Strøm, B. O., Krontveit, R. I., & Svanqvist, K. H. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0476-4 · Cited by 36
Loo, S. Y., Coulombe, J., Dell’Aniello, S., Brophy, J. M., Suissa, S., & Renoux, C. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019638 · Cited by 37
Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation
Gundlund, A., Xian, Y., Peterson, E. D., Butt, J. H., Gadsbøll, K., Olesen, J. B., Køber, L., Torp-Pedersen, C. T., Gislason, G., & Fosbøl, E. L. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0171 · Cited by 36
Yokoyama, S., Tanaka, Y., Nakagita, K., Hosomi, K., & Takada, M. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.28877 · Cited by 36
Gouveia, F., Bicker, J., Gonçalves, J., Alves, G., Falcão, A. C., & Fortuna, A. C. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.03.061 · Cited by 36
Cruz‐González, I., González-Ferreiro, R., Freixa, X., Gafoor, S. A., Shakir, S., Omran, H., Berti, S. L., Santoro, G., Kefer, J., Landmesser, U., et al. (2019) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2019.02.013 · Cited by 36
Königsbrügge, O., & Ay, C. (2019) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12250 · Cited by 36
Souverein, P. C., van den Ham, H. A., Huerta, C., Martín‐Merino, E., Montero, D., León-Muñoz, L. M., Schmiedl, S., Heeke, A., Rottenkolber, M., Andersen, M. T., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14450 · Cited by 36
Chao, T., Chiang, C., Chan, Y., Liao, J., Chen, T., Lip, G. Y. H., & Chen, S. (2021) · Heart Rhythm · doi:10.1016/j.hrthm.2021.02.018 · Cited by 36
New agents for DOAC reversal: a practical management review
White, K., Faruqi, U., & Cohen, A. T. (2022) · British Journal of Cardiology · doi:10.5837/bjc.2022.001 · Cited by 38
Akao, M., Ogawa, H., Masunaga, N., Minami, K., Ishigami, K., Ikeda, S., Doi, K., Hamatani, Y., Yoshizawa, T., Ide, Y., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-22-0023 · Cited by 36
Liew, A., O'Donnell, M. J., & Douketis, J. D. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12651 · Cited by 36
Acute cerebral infarcts in multiple arterial territories associated with cardioembolism
Novotný, V., Thomassen, L., Waje‐Andreassen, U., & Næss, H. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12606 · Cited by 36
Saji, N., Kimura, K., Aoki, J., Uemura, J., & Sakamoto, Y. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1209 · Cited by 35
Wilke, T., Groth, A., Pfannkuche, M., Harks, O., Fuchs, A., Maywald, U., & Krabbe, B. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1136-8 · Cited by 35
Khaji, A., & Kowey, P. R. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.06.007 · Cited by 35
García-Fernández, A., Roldán, V., Rivera‐Caravaca, J. M., Hernández‐Romero, D., Valdés, M., Vicente, V., Lip, G. Y. H., & Marín, F. R. (2017) · Scientific Reports · doi:10.1038/srep41565 · Cited by 35
Mazurek, M., Shantsila, E., Lane, D. A., Wolff, A., Proietti, M., & Lip, G. Y. H. (2017) · Stroke · doi:10.1161/strokeaha.116.016146 · Cited by 35
Hohnloser, S. H., Basic, E., & Näbauer, M. (2019) · Clinical Research in Cardiology · doi:10.1007/s00392-019-01437-7 · Cited by 35
Atrial fibrillation in the elderly.
Díez‐Villanueva, P., & Alfonso, F. (2019) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2019.01.005 · Cited by 39
Atrial Fibrillation and Dementia: Exploring the Association, Defining Risks and Improving Outcomes
Bunch, T. J., Galenko, O., Graves, K. G., Jacobs, V., & May, H. T. (2019) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2018.75.2 · Cited by 35
Updated Geriatric Cardiology Guidelines of the Brazilian Society of Cardiology - 2019
Moreira, A. A. C. D. M., Costa, E. F. D. A., Miranda, R. D., Wajngarten, M., Galera, S. C., Filho, A. C. D. A., Toledo, M. A. D. V., Alves, J. D. C., Moriguchi, E. H., Rodrigues, N. L., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190086 · Cited by 39
Gallinoro, E., D’Elia, S., Prozzo, D., Lioncino, M., Natale, F., Golino, P., & Cimmino, G. (2019) · Medicina · doi:10.3390/medicina55090587 · Cited by 37
Pasternack, R., Büchold, C., Jähnig, R., Pelzer, C., Sommer, M. G., Heil, A., Florian, P., Nowak, G., Gerlach, U., & Hils, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14646 · Cited by 35
Kirchhof, P. F., Haas, S. K., Amarenco, P., Hess, S., Lambelet, M., van Eickels, M., Turpie, A. G. G., Camm, A. J., & the XANTUS Investigators* (2020) · Journal of the American Heart Association · doi:10.1161/jaha.118.009530 · Cited by 35
Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status
Greco, A., & Capodanno, D. (2020) · Interventional Cardiology Reviews Research Resources · doi:10.15420/icr.2019.24 · Cited by 35
How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome
Cohen, H., & Isenberg, D. A. (2020) · Blood · doi:10.1182/blood.2020004942 · Cited by 35
Recommendations from the ICM-VTE: General
Delegates, T. I.-V. G. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.21.01531 · Cited by 36
Karayiannides, S., Lundman, P., Friberg, L., & Norhammar, A. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117735013 · Cited by 36
Abohelaika, S., Wynne, H., Avery, P. J., Robinson, B., Kesteven, P. J., & Kamali, F. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13046 · Cited by 34
Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors
Bentounes, N. K., Melicine, S., Martin, A., Smadja, D. M., & Gendron, N. (2023) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2023.04.002 · Cited by 34
Mobley, A., Subramanian, A., Champsi, A., Wang, X., Myles, P. R., McGreavy, P., Bunting, K. V., Shukla, D., Nirantharakumar, K., & Kotecha, D. (2024) · Nature Medicine · doi:10.1038/s41591-024-03049-9 · Cited by 38
Fabritz, L., Al-Taie, C., Borof, K., BREITHARDT, G. E., Camm, A. J., Crijns, H. J. G. M., Cardoso, V. R., Chua, W., van Elferen, S., Eckardt, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae611 · Cited by 34
Recent and future advances in intracerebral hemorrhage
Puy, L., Boe, N. J., Maillard, M., Kuchcinski, G., & Cordonnier, C. (2024) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2024.123329 · Cited by 36
Are New Oral Anticoagulant Dosing Recommendations Optimal for All Patients?
Powell, J. R. (2015) · JAMA · doi:10.1001/jama.2015.59 · Cited by 34
Patient values and preferences when choosing anticoagulants
Tamariz, L. J., Palacio, A., & Kirolos, I. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s64295 · Cited by 34
Sjögren, V., Byström, B., Renlund, H., Svensson, P. J., Oldgren, J., Norrving, B. G., & Själander, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181000 · Cited by 34
Dillinger, J., Aleil, B., Cheggour, S., Benhamou, Y., Béjot, Y., Maréchaux, S., Delluc, A., Bertoletti, L., & Lellouche, N. (2017) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2017.04.008 · Cited by 34
Plank, F., Beyer, C., Friedrich, G. J., Stuehlinger, M., Hintringer, F., Dichtl, W., Wildauer, M., & Feuchtner, G. M. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.019 · Cited by 34
Ujeyl, M., Köster, I., Wille, H., Stammschulte, T., Hein, R., Harder, S., Gundert‐Remy, U., Bleek, J., Ihle, P., Schröder, H., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2504-7 · Cited by 34
Bottino, R., Rago, A., Micco, P. D., D’Onofrio, A., Liccardo, B., Golino, P., Nigro, G., & Russo, V. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1661386 · Cited by 34
Douros, A., Renoux, C., Yin, H., Filion, K. B., Suissa, S., & Azoulay, L. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.10.008 · Cited by 34
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations
Caterina, R. D., Ageno, W., Agnelli, G., Chan, N., Diener, H., Hylek, E. M., Raskob, G. E., Siegal, D. M., Verheugt, F. W. A., Lip, G. Y. H., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1675816 · Cited by 35
Embolic strokes of undetermined source: theoretical construct or useful clinical tool?
Tsivgoulis, G. K., Katsanos, A. H., Köhrmann, M., Caso, V., Lemmens, R., Tsioufis, K. P., Paraskevas, G. P., Bornstein, N. M., Schellinger, P. D., Alexandrov, A. V., et al. (2019) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286419851381 · Cited by 34
Russo, V., Attena, E., Maio, M. D., Mazzone, C., Carbone, A., Parisi, V., Rago, A., D’Onofrio, A., Golino, P., & Nigro, G. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01923-9 · Cited by 36
Adherence to Anticoagulant Guideline for Atrial Fibrillation Improves Outcomes in Asian Population
Krittayaphong, R., Winijkul, A., Kunjara-Na-Ayudhya, R., Apiyasawat, S., Siriwattana, K., Kanjanarutjawiwat, W., Dutsadeevettakul, S., Lip, G. Y. H., & for the COOL-AF Investigators (2020) · Stroke · doi:10.1161/strokeaha.120.029295 · Cited by 34
Cipriano, A., Park, N., Pecori, A., Bionda, A. E., Bardini, M., Frassi, F., Lami, V., Leoli, F., Manca, M. L., Prato, S. D., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02576-w · Cited by 35
Ashraf, H., Agasthi, P., Shanbhag, A., Mehta, R. A., Rattanawong, P., Allam, M., Pujari, S. H., Mookadam, F., Freeman, W. K., Srivathsan, K. S., et al. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.12.022 · Cited by 35
Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines
Milling, T. J., Refaai, M. A., & Sengupta, N. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06728-y · Cited by 36
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation
Lee, S., Choi, E., Park, S. H., Jung, J., Han, K., Oh, S., & Lip, G. Y. H. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab004 · Cited by 34
Direct oral anticoagulants for unusual‐site venous thromboembolism
Riva, N., & Ageno, W. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12480 · Cited by 34
Cardiotoxicity of BTK inhibitors: ibrutinib and beyond
Christensen, B. W., Zaha, V. G., & Awan, F. T. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2067526 · Cited by 35
Update on antithrombotic therapy after percutaneous coronary revascularisation
Cuisset, T., Verheugt, F. W. A., & Mauri, L. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31936-0 · Cited by 35
Matching the NOAC to the Patient
Lip, G. Y. H., & Lane, D. A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.086 · Cited by 34
Patel, S. M., D, E. B. M., Steffel, J., Boriani, G., Palazzolo, M. G., Antman, E. M., Bohula, E. A., Carnicelli, A., Connolly, S. J., Eikelboom, J. W., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.066279 · Cited by 33
Krittayaphong, R., Treewaree, S., & Lip, G. Y. H. (2024) · EP Europace · doi:10.1093/europace/euae237 · Cited by 33
Eligibility and Preference of New Oral Anticoagulants in Patients With Atrial Fibrillation
Yoon, C. H., Park, Y. K., Kim, S. J., Lee, M. J., Ryoo, S., Kim, G., Chung, C., Lee, K. H., Kim, J. S., & Bang, O. Y. (2014) · Stroke · doi:10.1161/strokeaha.114.005599 · Cited by 33
Efficacy and safety of novel anticoagulants in the elderly.
Karamichalakis, N., Georgopoulos, S., Vlachos, K. G., Liatakis, I., Efremidis, M., Sideris, A., & Letsas, Κ. P. (2016) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2016.08.011 · Cited by 33
Ashburner, J. M., Singer, D. E., Lubitz, S. A., Borowsky, L. H., & Atlas, S. J. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.055 · Cited by 33
Pisters, R., van Vugt, S. P. G., Brouwer, M. A., Elvan, A., ten Holt, W. L., Zwart, P. A. G., Kirchhof, P. F., Crijns, H. J. G. M., & Hemels, M. E. W. (2017) · Netherlands Heart Journal · doi:10.1007/s12471-017-1009-9 · Cited by 33
Friberg, L., & Oldgren, J. (2017) · Open Heart · doi:10.1136/openhrt-2017-000682 · Cited by 33
Atrial fibrillation occurring transiently with stress
McIntyre, W. F., Connolly, S. J., & Healey, J. S. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000475 · Cited by 33
Hsu, J. C., & Freeman, J. V. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1024 · Cited by 32
Metadata
- Authors
- Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Thomas Jefferson University (US)
- St George's, University of London (GB)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Carmel Medical Center (IL)
- Cardiovascular Institute Hospital (JP)
- Corresponding author
- Ruff, Christian T
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9921
- Pages
- 955-962
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2152623033
- Cited by
- 5,051
- References
- 45
- Citations by year
- 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
- FWCI
- 49.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
- MeSH terms
- Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
